|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 274.85 DKK | +8.94% |
|
-10.24% | -41.36% |
| 03:47am | U.S. Futures Rise, European Stocks Mixed | DJ |
| Jun. 08 | Major European indices flat - Zealand Pharma plunges | FW |
Business description: Zealand Pharma A/S
At the end of 2025, the Group had a portfolio of 8 products in clinical development (including 3 in phase III, 3 in phase II and 2 in phase I), and 1 product in preclinical development.
Number of employees: 544
Sales by Activity: Zealand Pharma A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (DKK) |
|---|---|---|---|---|---|
Biotechnology | 293M | 104M | 343M | 62.69M | 9.21B |
Geographical breakdown of sales: Zealand Pharma A/S
| Fiscal Period: December | 2021 (DKK) | 2022 (DKK) | 2023 (DKK) | 2024 (DKK) | 2025 (DKK) |
|---|---|---|---|---|---|
Switzerland | - | - | - | - | 9.18B |
Denmark | - | 35M | 44.18M | 62.28M | 34.9M |
United States | 240M | 69M | 4.09M | 406K | - |
Germany | 53M | - | 295M | - | - |
Executive Committee: Zealand Pharma A/S
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 2022-03-29 | |
| Director of Finance/CFO | - | 2022-10-31 | |
Utpal Singh
CTO | Chief Tech/Sci/R&D Officer | - | 2025-04-22 |
David Kendall
CTO | Chief Tech/Sci/R&D Officer | 64 | 2022-06-01 |
Ivan Møller
COO | Chief Operating Officer | 54 | 2018-02-28 |
Composition of the Board of Directors: Zealand Pharma A/S
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | - | |
Kirsten Drejer
BRD | Director/Board Member | 69 | 2018-04-18 |
Leonard Kruimer
BRD | Director/Board Member | 68 | 2019-04-03 |
| Director/Board Member | 59 | 2019-12-31 | |
Anneline Nansen
BRD | Director/Board Member | 57 | 2021-08-31 |
Enrique Conterno
BRD | Director/Board Member | 59 | 2024-03-19 |
Elaine Sullivan
BRD | Director/Board Member | 65 | 2024-03-19 |
| Director/Board Member | 53 | 2024-03-19 | |
Adam Nygaard
BRD | Director/Board Member | - | 2024-03-19 |
| Director/Board Member | - | 2026-03-25 |
Holdings: Zealand Pharma A/S
| Name | Stocks | % | Valuation |
|---|---|---|---|
ZEALAND PHARMA A/S 1.27% | 907,905 | 1.27% | 46 M $ |
Company details: Zealand Pharma A/S
Bio Therapeutic Drugs
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +9.00% | -9.94% | -44.79% | +2.54% | 2.74B | |
| +0.58% | +10.61% | +49.51% | +110.59% | 54.81B | |
| -0.58% | -3.99% | +50.00% | +49.74% | 42.96B | |
| -2.93% | -6.76% | -21.19% | -21.54% | 21.62B | |
| -0.05% | -11.19% | +27.91% | +370.14% | 20.41B | |
| -1.45% | -14.80% | +15.15% | -33.24% | 16.03B | |
| -0.57% | +3.46% | +6.89% | -40.28% | 15.28B | |
| -1.82% | +2.90% | +20.24% | +167.39% | 13.01B | |
| +1.41% | -4.01% | +12.62% | - | 11.37B | |
| -4.47% | -10.18% | -31.47% | +666.85% | 10.95B | |
| Average | -0.07% | -6.85% | +8.49% | +141.35% | 20.92B | |
| Weighted average by Cap. | -0.58% | -3.25% | +25.15% | +119.45% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ZEAL Stock
- Company Zealand Pharma A/S
Select your edition
All financial news and data tailored to specific country editions
